David Cosgrove
Impact in
- Hepatology top 0.5%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 2%
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
Papers in
- Hepatology 27
- Hepatocellular Carcinoma Treatment and Prognosis 27
- Oncology 37
- Colorectal Cancer Treatments and Studies 13
- Pancreatic and Hepatic Oncology Research 6
- Co-authors
- Ihab R. KamelTimothy M. PawlikJean-François H. GeschwindJoseph M. HermanNikhil BhagatDiane K. ReyesRui‐Hua XuMiao‐Zhen Qiu
- Journals
- Journal of Clinical Oncology (17 papers)Journal of Gastrointestinal Surgery (5 papers)Radiology (3 papers)Cancer Research (3 papers)Annals of Surgical Oncology (3 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
David Cosgrove
75 papers receiving 2.7k citations
Peers
Comparison fields: 5 of 95
- Hepatology 963
- Oncology 1.1k
- Cancer Research 397
- Pulmonary and Respiratory Medicine 633
- Surgery 788
Countries citing papers authored by David Cosgrove
This map shows the geographic impact of David Cosgrove's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Cosgrove with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Cosgrove more than expected).
Fields of papers citing papers by David Cosgrove
This network shows the impact of papers produced by David Cosgrove. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Cosgrove. The network helps show where David Cosgrove may publish in the future.
Co-authors
The 25 scholars most cited alongside David Cosgrove, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 4 | |
| 3 | 2024 | 1 | |
| 4 | 2019 | 26 | |
| 5 | 2018 | 31 | |
| 6 | 2015 | 33 | |
| 7 | 2014 | 26 | |
| 8 | 2014 | 43 | |
| 9 | 2013 | 40 | |
| 10 | 2013 | 77 | |
| 11 | 2013 | 47 | |
| 12 | 2012 | 75 | |
| 13 | 2011 | 247 | |
| 14 | 2011 | 29 | |
| 15 | 2011 | 7 | |
| 16 | 2011 | 27 | |
| 17 | 2011 | 64 | |
| 18 | 2008 | 46 | |
| 19 | Infliximab attenuates joint destruction in early RA patients with ultrasonographic markers of poor prognosis. | 2002 | 1 |
| 20 | 1998 | 13 |
About David Cosgrove
David Cosgrove is a scholar working on Hepatology, Oncology, Cancer Research, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 80 papers that have together received 2.8k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (27 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (18 papers), Cancer Genomics and Diagnostics (14 papers), Colorectal Cancer Treatments and Studies (13 papers), PI3K/AKT/mTOR signaling in cancer (7 papers), MRI in cancer diagnosis (6 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Neuroendocrine Tumor Research Advances (6 papers). The work is most often cited by research in Hepatology (963 citations), Oncology (1.1k citations), Cancer Research (397 citations), Pulmonary and Respiratory Medicine (633 citations) and Surgery (788 citations). David Cosgrove has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Ihab R. Kamel, Timothy M. Pawlik, Jean-François H. Geschwind, Joseph M. Herman, Nikhil Bhagat, Diane K. Reyes, Timothy M. Pawlik, Rui‐Hua Xu, Miao‐Zhen Qiu and Jianming Hu. Their work appears in journals such as Journal of Clinical Oncology, Journal of Gastrointestinal Surgery, Radiology, Cancer Research and Annals of Surgical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.